Freedom from CLAD or CLAD-free survival: what's in a name?

Long-term outcomes after lung transplantation (LTx) remain inferior to other solid organs such as heart transplantation. This is largely a result of a high prevalence of chronic lung allograft dysfunction (CLAD), affecting approximately 50% of transplanted patients at 5 years post-transplant.1 Although Bronchiolitis Obliterans Syndrome (BOS) is the major clinical phenotype of CLAD (occurring in 70% of CLAD patients), Restrictive Allograft Syndrome (RAS), the other CLAD phenotype (30%), has a worse survival following diagnosis.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: Editorial Source Type: research